MedPath

Anxiety in Relation to Nausea and Vomiting in Pregnancy

Completed
Conditions
Nausea Gravidarum
Anxiety
Registration Number
NCT06059794
Lead Sponsor
Ain Shams Maternity Hospital
Brief Summary

The goal of this observational study is to learn more about the relation between anxiety (assessed by GAD-7 questionnaire) and the nausea and vomiting in pregnancy (objectively measured by PUQE score).

Participants will answer 2 questionnaires: (GAD-7) for anxiety; and (PUQE score) for nausea and vomiting.

Detailed Description

Study Procedures:

* Protocol approval will be sought from the ethical committee of the department of Obstetrics \& Gynecology, Faculty of Medicine, Ain Shams University.

* Recruitment of pregnant women complaining of nausea and vomiting in pregnancy (NVP) in first trimester will be done from the outpatient clinic and antenatal ward in Ain Shams University Maternity Hospital.

* An informed written consent will be taken from all participants before enrollment in the study.

* History taking, examination, and investigations (CBC, ultrasound, acetone in urine, serum sodium, potassium, alanine transaminase (ALT), aspartate transaminase (AST), serum creatinine) will be done to identify eligible patients according to the inclusion and exclusion criteria.

* PUQE score will be calculated for each patient. Patients will be classified into 3 groups (mild, moderate, severe) accordingly.

* GAD-7 questionnaire will be calculated for each patient. Degree of anxiety will be classified into 4 groups (minimal, mild, moderate, severe) accordingly.

* Data will be recorded in a case report form.

* Statistical analysis will be done accordingly.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
102
Inclusion Criteria
  • Pregnant women in first trimester complaining of NVP
  • Age (18-40) years
Exclusion Criteria
  • History of known medical problem (e.g., endocrine abnormalities, gastrointestinal disease).
  • Known current or past psychiatric disorder (e.g., depression, anxiety, bipolar disorder, delirium, eating disorders, and psychotic disorder)
  • Multiple pregnancy
  • Known obstetric complications (non-viable pregnancy; either ectopic pregnancy; gestational trophoblastic disease, or miscarriage).
  • Medications (including antidepressant, anti-psychotic or other psychiatric drugs during the last 6 months) or illegal drug or narcotic use that would affect the test results
  • Current or past history of cognitive incompetence which can make it difficult to understand how to score GAD-7 questionnaire.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Generalised Anxiety Disorder Assessment (GAD-7)Baseline

The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include "not at all", "several days", "more than half the days" and "nearly every day"

Pregnancy-Unique Quantification of Emesis (PUQE) scoreBaseline

The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy, based on quantification of the 3 physical symptoms of (nausea, vomiting and retching).

Secondary Outcome Measures
NameTimeMethod
Ketonuriaimmediately after the intervention

acetone in urine assessed by urine dipstick

Disturbance in Potassiumimmediately after the intervention

assessed by serum levels of Potassium.

Disturbance in Sodium.immediately after the intervention

assessed by serum levels of Sodium.

Dehydrationimmediately after the intervention

dehydration as detected clinically (like oliguria)

Hospital admissionimmediately after the intervention

Hospital admission

Hospital stayimmediately after the intervention

Duration of hospital stay in days

Trial Locations

Locations (1)

Ain Shams Maternity Hospital

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath